Phase I Dose-Escalation Study of Weekly Paclitaxel and Cisplatin Followed by Radical Hysterectomy in Stages IB2 and IIA2 Cervical Cancer
Conclusions: Weekly paclitaxel and cisplatin NAC for 3 courses can be tolerated with excellent short-term outcome. With the caveat of small number of patients, this study supports future phase II trials of weekly paclitaxel and cisplatin NAC for 4 to 5 cycles.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Gynecologic Source Type: research
More News: Cancer | Cancer & Oncology | Cancer of the Uterus | Carcinoma | Cervical Cancer | Cervical Discectomy | Chemotherapy | Genital Warts | Human Papillomavirus (HPV) | Hysterectomy | MRI Scan | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | OBGYN | PET Scan | Skin Cancer | Squamous Cell Carcinoma | Study | Toxicology